PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
203.49%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
185.87%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
185.87%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
-0.66%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
-29.56%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-185.91%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth 15-30% suggests significant increase. Howard Marks would demand explanation.
-92.79%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-92.79%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-3998.91%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-95.29%
Share count reduction needs verification. Benjamin Graham would examine sustainability.
-95.29%
Diluted share reduction needs verification. Benjamin Graham would examine sustainability.